New drug application of Paimpril accepted by State Drug Administration

On May 26, Sino Biopharmaceutical issued an announcement saying that the anti-PD-1 monoclonal antibody drug Anike (generic name: Paimpril, R&D code: AK105) jointly developed and commercialized by the company and Akeso has its application accepted by the State Drug Administration of China.

On May 26, Sino Biopharmaceutical issued an announcement saying that the anti-PD-1 monoclonal antibody drug Anike (generic name: Paimpril, R&D code: AK105) jointly developed and commercialized by the company and Akeso has its application accepted by the State Drug Administration of China.

It is used for the treatment of patients with relapsed or refractory Classical Hodgkin’s Lymphoma.

Classical Hodgkin Lymphoma (cHL) is a B-cell lymphoma, and is also one of the most common malignancies among young people. It has a single modal age distribution in China with a peak at around 40 years of age .

cHL is one of the few tumors that can be cured, and the most common therapy is chemotherapy plus radiotherapy, with the 5-year survival rate of patients as high as over 80%.

Although the first-line chemotherapy has a high clinical cure rate, a considerable portion of patients are insensitive to chemotherapy and approximately 5% to 10% of patients do not respond to the initial treatment.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/27/new-drug-application-of-paimpril-accepted-by-state-drug-administration/.

Leave a Reply

Your email address will not be published. Required fields are marked *